drugset / Trial / NCT00090493
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
Timeline
- Start
- 2004-06
- Primary completion
- 2007-07
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAGE-A3 | Vaccine | 300 ug | Subcutaneous |
| Subject | NY-ESO-1 | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | 500 ug | Subcutaneous |